[A22-31] Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 01.06.2022
Project no.:
A22-31
Commission:
Commission awarded on 25.03.2022 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A19-48 | Lorlatinib (NSCLC) - Benefit assessment according to §35a Social Code Book V | Commission completed |